Abstract
Purpose
Surveillance after orchiectomy alone has become popular in the management of clinical stage I nonseminomatous germ cell testicular tumors (CSI NSGCTT), and adjuvant chemotherapy has been accepted in high-risk CSI NSGCTT. Because of the late toxicity of standard radiotherapy in CSI testicular seminoma (SGCTT), this therapeutic approach has been accepted also in the management of CSI SGCTT. In the current study, we analyzed single-center experience with risk-adapted therapeutic approaches (active surveillance and adjuvant chemotherapy) in patients with CSI SGCTT.
Patients and methods
The study analyzed a total of 90 patients collected at a single center from April 2008 to March 2015 with CSI SGCTT who were stratified into two groups according to risk-adapted therapeutic approaches.
Results
In the group A (low-risk CSI SGCTT—no rete testis invasion, tumor size <4 cm, pT1 stage), which consisted of 74 patients who underwent surveillance, relapse occurred in seven (9.5 %) patients after a mean follow-up of 14.5 months. In the group B (high-risk CSI SGCTT—rete testis invasion, tumor size >4 cm or pT ≥ 2 stage), which consisted of 16 patients who were treated with adjuvant chemotherapy, relapse occurred in two (12.5 %) patients after a mean follow-up of 13.8 months. Overall survival of patients in both groups was 100 %. The statistically significant difference in progression-free survival between these two groups was not found.
Conclusions
Radiotherapy is currently not recommended as an adjuvant treatment in CSI SGCTT patients. The benefit of using risk-adapted therapeutic approaches in CSI SGCTTs patients is evident.
Similar content being viewed by others
References
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S et al (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase no. 11 [Internet]. IARC, Lyon. http://globocan.iarc.fr
Oldenburg J, Fossa SD, Nuver J, Heidenreich A, Schmoll HJ et al (2013) Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):25–32
De Wit R, Fizazi K (2006) Controversies in the management of clinical stage I testis cancer. J Clin Oncol 24:5482–5492
Oldenburg J, Aparicio J, Beyer J, Cohn-Cedermark G, Cullen M et al (2015) Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Ann Oncol 26:833–838
Nichols CR, Roth B, Albers P, Einhorn LH, Foster R et al (2013) Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol 31:3490–3493
Tandstad T, Smaaland T, Solberg A, Bremnes RM, Langberg CW et al (2011) Management of seminomatous testicular cancer: a binational prospective population-based study from the SWENOTECA study group. J Clin Oncol 29:719–725
Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C et al (2013) Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 24:878–888
Chung P, Daugaard G, Tyldesley S, Panzarella T, Kollmannsberger C et al (2010) Prognostic factors for relapse in stage I seminoma managed with surveillance: a validation study. J Clin Oncol 28:15s (Suppl); abstr. 4535
Aparicio J, Maroto P, Del Muro XG, Guma J, Sanchez-Munoz A et al (2011) Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol 29:4677–4681
Oliver RTD, Mason MD, Mead GM, Von der Maase H, Rustin GJS et al (2005) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366:293–300
Oliver RTD, Mead GM, Rustin GJ, Joffe JK, Aass N et al (2011) Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 29:957–962
Krege S, Beyer J, Souchon R, Albers P, Albrecht W et al (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 53:478–496
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G et al (2015) Guidelines on testicular cancer, EAU, Arnhem, The Netherlands, ISBN/EAN: 978-90-79754-80-9
Chung P, Warde P (2006) Surveillance in stage I seminoma. Urol Oncol 24:75–79
Cohn-Cedermark G, Stahl O, Tandstad T (2015) Surveillance versus adjuvant therapy of clinical stage I testicular tumors—a review and the SWENOTECA experience. Andrology 3:102–110
Vaugh DJ (2015) Primum non nocere: active surveillance for cinical stage I testicular cancer. J Clin Oncol 33(1):9–12
Pectasides D, Pectasides E, Constantinidou A, Aravantinos G (2009) Stage I testicular seminoma: management and controversies. Crit Rev Oncol Hematol 71:22–28
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
This publication is the result of the implementation of project APVV-0016-11 supported by the Slovak Research and Development Agency.
Rights and permissions
About this article
Cite this article
Ondrusova, M., Ondrus, D., Miskovska, V. et al. Management of clinical stage I testicular seminoma: active surveillance versus adjuvant chemotherapy. Int Urol Nephrol 47, 1143–1147 (2015). https://doi.org/10.1007/s11255-015-1002-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-015-1002-4